Avantor, Inc. (NYSE:AVTR – Get Free Report) has been assigned an average recommendation of “Hold” from the sixteen analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $13.9667.
A number of research firms have recently weighed in on AVTR. Jefferies Financial Group cut Avantor to an “underperform” rating in a report on Wednesday. UBS Group set a $12.00 target price on shares of Avantor in a research report on Thursday, October 30th. Bank of America cut shares of Avantor from a “buy” rating to a “neutral” rating and set a $13.00 price target for the company. in a research report on Monday. JPMorgan Chase & Co. restated a “neutral” rating and issued a $12.00 price objective (down from $14.00) on shares of Avantor in a report on Thursday, October 30th. Finally, Evercore ISI dropped their target price on shares of Avantor from $16.00 to $14.00 and set an “outperform” rating for the company in a report on Thursday, October 30th.
Get Our Latest Research Report on AVTR
Avantor Stock Down 1.1%
Avantor (NYSE:AVTR – Get Free Report) last released its quarterly earnings data on Wednesday, October 29th. The company reported $0.22 EPS for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.01). The business had revenue of $1.62 billion during the quarter, compared to analyst estimates of $1.65 billion. Avantor had a negative net margin of 1.25% and a positive return on equity of 10.91%. The company’s revenue was down 5.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.26 earnings per share. Avantor has set its FY 2025 guidance at 0.880-0.920 EPS. On average, equities research analysts predict that Avantor will post 1.06 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director Gregory L. Summe bought 100,000 shares of the company’s stock in a transaction on Thursday, October 30th. The stock was bought at an average cost of $11.25 per share, with a total value of $1,125,000.00. Following the transaction, the director directly owned 300,000 shares in the company, valued at $3,375,000. The trade was a 50.00% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Sanjeev K. Mehra purchased 350,000 shares of the business’s stock in a transaction on Friday, December 5th. The shares were acquired at an average price of $11.09 per share, for a total transaction of $3,881,500.00. Following the completion of the purchase, the director directly owned 350,000 shares of the company’s stock, valued at approximately $3,881,500. This trade represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 1.20% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in the business. Manhattan West Asset Management LLC lifted its holdings in Avantor by 65.3% during the 3rd quarter. Manhattan West Asset Management LLC now owns 223,392 shares of the company’s stock worth $2,788,000 after buying an additional 88,241 shares in the last quarter. Voss Capital LP grew its stake in shares of Avantor by 905.6% in the third quarter. Voss Capital LP now owns 4,525,000 shares of the company’s stock worth $56,472,000 after acquiring an additional 4,075,000 shares in the last quarter. Coldstream Capital Management Inc. purchased a new stake in shares of Avantor during the third quarter worth $172,000. Danica Pension Livsforsikringsaktieselskab acquired a new stake in shares of Avantor in the third quarter valued at $787,000. Finally, Danske Bank A S purchased a new position in Avantor in the third quarter valued at $85,000. Institutional investors and hedge funds own 95.08% of the company’s stock.
About Avantor
Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.
Read More
- Five stocks we like better than Avantor
- P/E Ratio Calculation: How to Assess Stocks
- Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport
- What Are Some of the Best Large-Cap Stocks to Buy?
- Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock
- Consumer Staples Stocks, Explained
- Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
